Treace Medical, Q3 2026 Earnings Call Transcript

Treace Medical expects to return to revenue growth in Q4, driven by rising procedure volumes, seasonal demand, and contributions from new products. Q3 revenue fell 4% year over year to $48.3 million, reflecting a shift toward lower-priced minimally invasive products and fewer distributor stocking orders, while procedure volume grew at a double-digit rate. The company narrowed 2026 revenue guidance to $206–210 million and expects an adjusted EBITDA loss of $1–2 million, with cash usage down about 50% from 2025. Expanded bunion and foot-and-ankle offerings are intended to increase adoption among existing surgeons and broaden the addressable market; management says new launches could support growth above market rates, but will provide a 2027 outlook after assessing Q4 volumes and launch performance. ASPs may remain pressured as lower-priced products enter the mix, while new midfoot and hindfoot technologies offer higher-value cases.